An interventional study of Real-time AI guidance for eFAST and Nurse-performed eFAST with AI guidance in Hemoperitoneum, Ascites and Intra-Abdominal Fluid Collection, sponsored by Oslo University Hospital. Not yet recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Oslo University Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluates whether nurses with real-time artificial intelligence (AI) guidance, and without a remote expert, can perform extended Focused Assessment with Sonography in Trauma (eFAST) with diagnostically usable image quality in patients who have recently undergone liver surgery. Each patient is examined twice: first by a nurse using a handheld ultrasound probe with AI guidance, then by a radiologist as reference standard. The study measures image quality, agreement on free fluid between the nurse and the reference standard, and examination duration.
In the precursor study (NCT06594562), nurses performed eFAST after liver surgery with real-time guidance from a remote expert. This study replaces the remote expert with real-time AI guidance.
Design: prospective single-arm diagnostic agreement study at Oslo University Hospital, Rikshospitalet, target 30 patients. Each patient is examined twice. A ward nurse performs AI-guided eFAST with a Clarius handheld probe (index test). An experienced radiologist performs an independent eFAST within one hour (reference standard). CT replaces the radiologist's eFAST as reference when clinically indicated and performed within 24 hours.
AI model: developed by SINTEF, trained on recordings from the precursor study, and locked before enrollment. It provides real-time image recognition to guide the operator.
Analysis: the abdomen (right and left upper quadrant, suprapubic) is analysed per patient and per window. Results are compared descriptively with the precursor cohort. Reporting follows STARD-AI and DECIDE-AI. Enrollment ends at 30 patients or after three months.
248 studies on the registry are indexed under Ascites; 57 are open to participants now.
This study's planned enrollment of 30 is below the median of 54 across 180 interventional studies indexed under Ascites.
Browse Ascites studies →Oslo University Hospital is the lead sponsor of 835 studies on the registry; 150 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Operators are five or more ward nurses with limited point-of-care ultrasound experience, who give separate consent to registration of performance data. Reference examinations are performed by experienced radiologists at Oslo University Hospital.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled patients receive an AI-guided eFAST by a ward nurse, followed by a reference examination by a radiologist, or CT when clinically indicated.
Device: Real-time AI guidance for eFAST · Diagnostic Test: Nurse-performed eFAST with AI guidance · Diagnostic Test: Reference standard: radiologist eFAST or CT
Software model developed by SINTEF, running on a laptop connected to a Clarius wireless handheld ultrasound probe. Provides real-time structural image recognition to guide the operator.
Index test. eFAST performed by a ward nurse with limited ultrasound experience, guided in real time by the AI model, without a remote expert. Windows: right and left upper quadrant, suprapubic (sagittal and transverse), subxiphoid pericardial and bilateral lung. The nurse records a yes/no free fluid assessment per window.
Independent bedside eFAST performed by an experienced radiologist within one hour after the index test, recorded yes/no per window. CT is the reference when clinically indicated and performed within 24 hours of the ultrasound examinations, and takes precedence when CT and radiologist eFAST disagree. The radiologist also scores image quality of the nurse's stored clips.
Image quality per abdominal eFAST window
Likert scale 1 to 5 per window (right upper quadrant, left upper quadrant, suprapubic), scored by the reference radiologist on stored clips from the nurse's examination, based on how confidently the clip can be interpreted. Same scale as in the precursor study (NCT06594562). Threshold for interpretation: median of 3 or higher per window.
Time frame: Within 1 hour after the index examination
Agreement on free fluid in the abdomen
Percent agreement (concordance rate, p\_o) between the nurse's AI-assisted yes/no assessment and the reference standard (radiologist eFAST or CT), per patient. The abdomen is positive if fluid is seen in at least one of the right upper quadrant, left upper quadrant or suprapubic windows. Threshold for interpretation: 80 percent or higher.
Time frame: Within 24 hours after the index examination (reference eFAST within 1 hour, CT within 24 hours)
Examination duration
Time from probe on patient to end of examination, minutes:seconds, reported as median with interquartile range. Threshold for interpretation: median of 10 minutes or less.
Time frame: During the index examination, up to 1 hour
Chance-corrected agreement on free fluid
Gwet's AC1 and Cohen's kappa (unweighted) between nurse and reference standard, for the abdomen and per abdominal window, with bootstrap confidence intervals. Percent agreement per abdominal window is also reported.
Time frame: Within 24 hours after the index examination
Diagnostic accuracy of AI-guided nurse eFAST
Sensitivity, specificity, positive and negative predictive value, and positive and negative percent agreement against the reference standard, with Wilson 95 percent confidence intervals.
Time frame: Within 24 hours after the index examination
Proportion of diagnostic windows
Proportion of windows where the nurse obtained the key anatomical structure, reported per eFAST window.
Time frame: During the index examination, up to 1 hour
Cognitive workload (NASA-TLX)
NASA Task Load Index, 0 to 20 scale, completed by the nurse.
Time frame: Immediately after each index examination
User experience
Operator confidence questionnaire (10 items, adapted from Hurd et al. 2025) and System Usability Scale (0 to 100), completed by the nurse.
Time frame: Immediately after each index examination
Change in examination duration over successive examinations
Learning curve. Change in examination duration (minutes:seconds) with examination number per nurse, analysed with a linear mixed-effects model.
Time frame: Through study completion, an average of 3 months
Change in image quality over successive examinations
Learning curve. Change in image quality score with examination number per nurse, analysed with a linear mixed-effects model. Image quality is scored on a Likert scale from 1 to 5, where higher scores mean better image quality.
Time frame: Through study completion, an average of 3 months
Change in NASA Task Load Index score over successive examinations
Learning curve. Change in NASA Task Load Index (NASA-TLX) score with examination number per nurse, analysed with a linear mixed-effects model. The score ranges from 0 to 20, where higher scores mean higher workload.
Time frame: Through study completion, an average of 3 months
Image quality, subxiphoid pericardial window (exploratory)
Likert scale 1 to 5, scored as for the primary image quality outcome. Threshold for interpretation: median of 3 or higher.
Time frame: Within 1 hour after the index examination
Plan to share: No — Individual participant data are stored in Oslo University Hospital's approved research storage. Public sharing is not covered by the current data protection approvals.
Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.
Of 33 interventional studies with no phase under Ascites, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 62. This study's planned 3 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.